These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36813278)

  • 1. Ezetimibe plus moderate-intensity statin versus high-intensity statin.
    Drug Ther Bull; 2023 Mar; 61(3):38. PubMed ID: 36813278
    [No Abstract]   [Full Text] [Related]  

  • 2. In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.
    Kelsey MD; Newby LK
    Ann Intern Med; 2022 Nov; 175(11):JC126. PubMed ID: 36315955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Kim BK; Hong SJ; Lee YJ; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Cho YH; Lee SJ; Ahn CM; Kim JS; Ko YG; Choi D; Jang Y; Hong MK;
    Lancet; 2022 Jul; 400(10349):380-390. PubMed ID: 35863366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial.
    Lee YJ; Lee SH; You SC; Lee YH; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    Diabetes Obes Metab; 2024 Mar; 26(3):829-839. PubMed ID: 37994242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.
    Lee SH; Lee YJ; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Park KH; Lee JH; Choi YJ; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    J Am Coll Cardiol; 2023 Apr; 81(14):1339-1349. PubMed ID: 37019580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial.
    Lee B; Hong SJ; Rha SW; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Kim HK; Kim U; Choi YJ; Lee YJ; Lee SJ; Ahn CM; Ko YG; Kim BK; Choi D; Hong MK; Jang Y; Kim JS
    Atherosclerosis; 2023 Dec; 386():117373. PubMed ID: 37995599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
    Lee YJ; Cho JY; You SC; Lee YH; Yun KH; Cho YH; Shin WY; Im SW; Kang WC; Park Y; Lee SY; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    Eur Heart J; 2023 Mar; 44(11):972-983. PubMed ID: 36529993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.
    Ah YM; Jeong M; Choi HD
    PLoS One; 2022; 17(3):e0264437. PubMed ID: 35245303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    Lee SJ; Joo JH; Park S; Kim C; Choi DW; Hong SJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Nam CM; Hong MK
    J Am Coll Cardiol; 2023 Aug; 82(5):401-410. PubMed ID: 37495276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
    Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
    Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial.
    Park JI; Lee SJ; Hong BK; Cho YH; Shin WY; Lim SW; Kang WC; Park Y; Lee SY; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS;
    EClinicalMedicine; 2023 Apr; 58():101933. PubMed ID: 37090440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study.
    Kim J; Kang D; Park H; Kang M; Choi KH; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Gwon HC; Guallar E; Cho J; Hahn JY
    Cardiovasc Drugs Ther; 2023 Feb; 37(1):141-150. PubMed ID: 34533691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial.
    Yu CC; Lai WT; Shih KC; Lin TH; Lu CH; Lai HJ; Hanson ME; Hwang JJ
    BMC Res Notes; 2012 May; 5():251. PubMed ID: 22621316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies.
    Shin KH; Choi HD
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):395-406. PubMed ID: 34927215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Masana L; Pedro-Botet J; Civeira F
    Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.